‹ All Posts
Hemraj Singh Sikarwar

4 hours ago · SEBI Registration INH000016719

Orchid Pharma returns to profit, but debt needs attention

Orchid Pharma Limited (NSE: ORCHPHARMA) reported consolidated revenue of ₹341.27 crore in Q2 FY27, up 14.4% year-on-year. Net profit stood at ₹28.59 crore, compared with a loss of ₹0.90 crore in the corresponding quarter last year. The company also recorded an improvement in operating performance. Consolidated operating profit increased to approximately ₹24.1 crore from a loss of ₹1.5 crore a year ago. Operating margin improved to 7.1% from negative 0.8%. The recovery is encouraging, particularly after a challenging period for the business. Orchid Pharma is working on strengthening its integrated cephalosporin manufacturing platform. Two important projects are the 7ACA project and the Cefiderocol project. These investments are aimed at expanding its manufacturing capabilities and product portfolio. However, there is another side to the expansion story. Consolidated net debt increased to ₹487 crore as of September 30, 2026, compared with ₹218 crore at the end of March 2026. The company has been funding its capital expenditure partly through additional borrowings. On the positive side, consolidated cash generated from operating activities during H1 FY27 was approximately ₹118 crore, compared with a negative operating cash flow in the corresponding period last year. **My view:** The return to profitability and improvement in operating margins are positive developments. However, rising debt and ongoing capital expenditure make execution particularly important. Investors should monitor whether the new projects begin contributing to revenue and whether operating cash flows remain strong enough to support the investment programme. The quality and sustainability of earnings will matter more than one quarter of improved numbers. Disclaimer: This post reflects my independent analysis based on publicly available information and is shared for educational and informational purposes. ORCHPHARMA

#PersonalFinance#EquityResearch
71 likes·42 comments